** U.S.-listed shares of German drugmaker CureVac 5CV.DE, CVAC.O rise 15.4% to $3.23 premarket
** European Patent Office upheld a CVAC mRNA patent after it was challenged by rival BioNTech 22UAy.DE, co said on Thursday
** A German court will decide on July 1 if BioNTech infringed this patent
** The dispute is part of a larger ongoing patent battle between CureVac and BioNTech over mRNA tech used in COVID-19 vaccines
** CVAC fell 8.2% in the last 12 months
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。